Estrella Immunopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Estrella Immunopharma, Inc. carries a market capitalization of 40.36M, placing it among publicly traded companies globally. Its enterprise value stands at -1.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 40.36M |
| Enterprise Value | -1.93M |
Share Statistics
Estrella Immunopharma, Inc. currently has 42.67M shares outstanding.
| Shares Outstanding | 42.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Estrella Immunopharma, Inc. maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.24 |
| Quick Ratio | 0.24 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -215.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 825.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Estrella Immunopharma, Inc.'s stock has gained approximately 176.00849% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | 176.00849% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.25M, while operating income came in at -13.25M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.25M |
| Pretax Income | -13.25M |
| Net Income | -13.25M |
| EBITDA | -13.25M |
| EBIT | -13.25M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -39.28M, with working capital of -6.77M providing operational flexibility.
| Cash & Cash Equivalents | 1.93M |
| Total Debt | N/A |
| Net Debt | -1.93M |
| Equity (Book Value) | -39.28M |
| Book Value Per Share | N/A |
| Working Capital | -6.77M |
Cash Flow
Estrella Immunopharma, Inc. produced -8.02M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.02M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.02M |
| FCF Per Share | N/A |
Scores
Estrella Immunopharma, Inc. posts an Altman Z-Score of -29.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.22 |